Test Price
2,800 AED✅ Home Collection Available
KIF1A Gene SPG30 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين KIF1A المرتبط بـ SPG30 (تسلسل الجيل الجديد) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary / ملخص تنفيذي
يقدم هذا الفحص الجيني المتطور تشخيصًا دقيقًا لطفرات جين KIF1A المسببة للشلل النصفي التشنجي الوراثي (SPG30) مع ضمان دقة 99.9% تحت إشراف هيئة الصحة بدبي ووفق معايير الجودة العالمية.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Accredited NGS Processing.
- Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain transport & VIP Mobile Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test clinical guidance to interpret results with a senior genetic counsellor.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview: Precision Genetic Diagnosis for SPG30
The KIF1A gene SPG30 NGS test sequences the entire coding region of the KIF1A gene to identify pathogenic variants responsible for autosomal dominant hereditary spastic paraplegia type 30. يساعد هذا التحليل في تأكيد التشخيص الوراثي وتوجيه خطة العلاج العصبي. This NGS‑based assay provides superior coverage compared to single‑variant tests.
| Feature | Our KIF1A NGS Test | Standard Genetic Panel |
|---|---|---|
| Methodology | Full‑gene Next Generation Sequencing (NGS) with copy number analysis | Targeted mutation genotyping or limited Sanger sequencing |
| Diagnostic Sensitivity | >99.9% for clinically relevant variants | Variable, often <70% for novel mutations |
| Turnaround Time | 3–4 Weeks | 2–6 Weeks (often without full bioinformatics) |
| Price | 2800 AED | 1900–3200 AED |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy (DHA: 61713011) advises: “While this NGS test delivers high‑resolution genetic data, it must always be correlated with a full neurological examination and family history. A confirmed KIF1A mutation can guide prognosis and family planning, but it is not a substitute for ongoing specialised care. I urge every patient to discuss their results with a clinical geneticist to fully understand the implications.”
⚠️ Important Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Genetic test results do not justify abrupt changes in therapy.
Exclusion Criteria & Safety Information:
- Not suitable for individuals with active systemic infection or recent blood transfusion (within 4 weeks) without physician clearance.
- Testing of minors requires a DHA‑approved genetic counselling session and parental consent in compliance with the UAE Clinical Genomic Services Law 2026.
- Emergency Red Flags: Sudden loss of ambulation, acute vision changes, status epilepticus, or severe respiratory distress require immediate ER evaluation; the genetic test result does not replace emergency care.
- This test is not a standalone diagnostic tool; it should be ordered and interpreted by a Neurologist, Clinical Geneticist, or Genetic Counsellor.
Regulatory Adherence: Our laboratory strictly follows Federal Decree‑Law No. 41 of 2024 (Art. 87) for genetic data protection and UAE PDPL. All samples are processed under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) protocols.
Frequently Asked Questions / الأسئلة الشائعة
1. What exactly does the KIF1A gene SPG30 test analyse?
The KIF1A gene SPG30 test sequences your entire KIF1A gene to detect mutations causing hereditary spastic paraplegia type 30. This NGS assay reads every exon and flanking intronic regions, identifying single nucleotide variants, indels, and copy number changes with >99.9% accuracy. It is the most comprehensive molecular diagnostic tool for SPG30.
١. ما الذي يحلله تحليل جين KIF1A المرتبط بـ SPG30؟
يقوم فحص جين KIF1A بتسلسل الجين الكامل للكشف عن الطفرات المسببة للشلل النصفي التشنجي الوراثي من النوع 30. تغطي تقنية (NGS) جميع الإكسونات والمناطق المجاورة بدقة تزيد عن 99.9%، مما يوفر تحليلاً شاملاً للتشخيص الجيني.
2. How accurate is this genetic compared to older methods?
With Next‑Generation Sequencing (NGS), diagnostic sensitivity exceeds 99.9% for pathogenic variants, ensuring reliable genetic diagnosis. Unlike targeted genotyping, NGS uncovers both common and novel mutations, reducing false‑negative rates to less than 0.1%. Our ISO 9001:2015 certified lab uses validated bioinformatics pipelines.
٢. ما مدى دقة هذا التحليل الجيني مقارنة بالطرق القديمة؟
تتجاوز حساسية التشخيص 99.9% باستخدام تسلسل الجيل الجديد (NGS)، مما يضمن كشفًا موثوقًا للطفرات. ويكتشف الطفرات الجديدة والنادرة التي قد تفوتها الفحوصات التقليدية، مع نسبة خطأ أقل من 0.1% تحت معايير جودة صارمة.
3. How long will I wait for the result and what is included?
Turnaround time is 3 to 4 weeks from sample receipt, including comprehensive bioinformatics analysis and clinical interpretation. Your report will be signed by a board‑certified geneticist and includes variant classification (ACMG guidelines), clinical correlation, and a complimentary tele‑consultation with a genetic counsellor.
٣. ما مدة انتظار النتيجة وماذا يشمل التقرير؟
تستغرق النتيجة 3 إلى 4 أسابيع من استلام العينة، وتشمل تحليلاً معلوماتياً حيوياً شاملاً وتفسيرًا سريريًا معتمدًا. يتضمن التقرير تصنيف الطفرة وفق معايير ACMG واستشارة هاتفية مجانية مع مستشار وراثي معتمد.
UAE Legal Compliance: Federal Decree‑Law No. 41 of 2024 (Art. 87), CDS Law 2026, UAE PDPL. All genetic testing performed under DHA license 9834453.
Support & Booking: WhatsApp +971 54 548 8731 | Home Collection 8 AM – 11 PM daily.
© 2026 Centers Healthcare. ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Last reviewed: March 2026.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians